Domov › Miastenija gravis › Kalifornija

Klinične študije za Miastenija gravis v Kalifornija

20 študij za Miastenija gravis išče udeležence na lokacijah v Kalifornija.

Mesta v Kalifornija

Uradno besedilo študije (angleško)

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Neurology Center of North Orange County, Fullerton
The Neurology Group, Pomona

Vključevanje udeležencevFaza 3

Starost 18–74 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07217587

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

Cinical Study Site, Pasadena

Vključevanje udeležencevFaza 3

Starost 18–80 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07647510

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Profound Research LLC - Carlsbad, Carlsbad

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07294170

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Profound Research LLC - Carlsbad, Carlsbad

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT07284420

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Tri Valley Neurology Medical Associates Inc., Mission Hills

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07501702

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

TG Therapeutics Investigational Trial Site, La Jolla

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06680037

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

University of California Irvine Medical Center, Irvine

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 21. avg. 2026 · NCT06414954

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Hoag Memorial Hospital Presbyterian, Newport Beach
Stanford Neuroscience Health Center, Palo Alto

Vključevanje udeležencevFaza 1

Starost 18–75 · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT07304154

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

University of California Irvine, Orange
UC Davis, Department of Neurology, Sacramento
University of California, San Francisco, San Francisco

Vključevanje udeležencevFaza 1/2

Starost 18–70 · Vsi spoli · Posodobljeno 13. avg. 2026 · NCT06359041

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

University of California-San Francisco, San Francisco

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci

Starost 18–64 · Ženske · Posodobljeno 11. avg. 2026 · NCT06940323

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Aurinia Investigational Site, Pasadena

Vključevanje udeležencevFaza 1/2

Starost 18–85 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT07596901

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Lucile Packard Children's Hospital Stanford, Palo Alto
UCSF Benioff Children's Hospital, San Francisco

Vključevanje udeležencevFaza 2/3

Starost 2–17 · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT05265273

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Site Number - 1010, Carlsbad
Site Number - 1028, Irvine
Site Number - 1023, Los Angeles
in še 2

Vključevanje udeležencevFaza 3

Starost 18–80 · Vsi spoli · Posodobljeno 30. jul. 2026 · NCT07039916

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Ronald Reagan UCLA Medical Center, Los Angeles
University of California, Irvine, Orange
Stanford University Medical Center, Palo Alto

Vključevanje udeležencevFaza 2/3

Starost 18–75 · Vsi spoli · Posodobljeno 29. jul. 2026 · NCT06193889

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Care Access Research, Pasadena

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT04951622

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

University of Southern California, Los Angeles
University of California Irvine, Orange
University of California San Francisco (UCSF), San Francisco

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 18. jun. 2026 · NCT06456580

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

UCLA Medical Center, Los Angeles
University of California, Irvine, Orange
Stanford Hospital, Palo Alto

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 25. feb. 2026 · NCT06626919

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Clinical Trial Site, Fresno
Clinical Trial Site, Orange
Clinical Trial Site, Rancho Mirage
in še 1

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 18. feb. 2026 · NCT04202341

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,, San Francisco

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 17. feb. 2026 · NCT06298565

Vitaccess Real MG Registry

UCI Health, Orange

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 29. jul. 2025 · NCT06064461

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.